niraparib + aromatase inhibitors

This combination therapy consists of the PARP inhibitor niraparib and standard aromatase inhibitors (AIs). It is being evaluated in the Phase II LUZERN trial (NCT04240106) for the treatment of hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic or advanced breast cancer. The regimen specifically targets patients with germline BRCA1/2 mutations or homologous recombination deficiency (HRD) who have developed resistance to prior aromatase inhibitor-based therapy. Niraparib acts by inhibiting PARP1 and PARP2 enzymes, which are critical for DNA repair, leading to synthetic lethality in cells with existing DNA repair defects. Aromatase inhibitors block the conversion of androgens to estrogens, thereby reducing the hormonal drive of the cancer. The trial is sponsored by MedSIR and supported by GSK.

Other names

niraparib plus aromatase inhibitorsniraparib + AIs